The clinical effectiveness of insulin glargine in patients with Type I diabetes in Brazil: findings and implications.

Aim: Published studies have challenged the cost-effectiveness of insulin glargine versus neutral protamine hagedorn (NPH) insulins in Brazil with limited evidence of increased effectiveness despite considerably higher acquisition costs. However, still a controversy. Consequently, there is a need to address this.